Noticias – MedicalCooling
MedicalCooling · Noticias
Noticias
Actualizaciones importantes sobre evidencia científica, desarrollo clínico, regulación, reembolso, patentes, tecnología, financiación y colaboraciones que pueden influir en la estrategia de AIRCHILL.
AIRCHILL sigue siendo una tecnología médica en desarrollo, sin marcado CE ni autorización de la FDA. Las noticias distinguen la evidencia externa y los cambios del mercado de las afirmaciones específicas de AIRCHILL y explican sus implicaciones para el programa de desarrollo.
Algunas noticias individuales pueden seguir apareciendo en inglés.
Últimas noticias
-
TBI field-biomarker update: dried capillary plasma could simplify future EMS trial sampling
A 4 September 2026 peer-reviewed TBI methods study shows that dried capillary plasma can preserve GFAP, UCH-L1, NfL and Tau signals, creating a potential future EMS sampling option without changing AIRCHILL clinical claims.
-
ESICM Call 2 is open: opportunity for a neutral ICU consensus project
ESICM Call 2 is open from 7 September to 5 October 2026 for guidelines, consensus statements and position papers, creating a time-limited scientific-network opportunity relevant to early neuroprotection and temperature-management methodology.
-
4 September 2026: new trial benchmarks for ventilation, peri-EVT physiology and device-based cooling
New external trial records sharpen AIRCHILL human-factors, peri-EVT ventilation and regulatory-development planning without changing the current efficacy claims.
-
Technology and IP watch: intranasal cooling, BrainCool/ZOLL, corpuls and liquid ventilation
Recent competitor, patent and platform developments sharpen AIRCHILL’s differentiation around early respiratory cooling, integrated ventilation and EMS interoperability.
-
Funding and partnership opportunities: MEDICA, accelerators, G-BA and international programmes
Time-sensitive 2026 opportunities include MEDICA competitions, MedTech accelerators, German innovation funding, EU programmes and clinical-networking routes.
-
Market access 2026: Germany, EU HTA, NHS value-based procurement and US reimbursement windows
Several 2026 policy and reimbursement changes could materially shape AIRCHILL evidence generation, from German emergency-care reform and G-BA funding to EU HTA consultation and NHS value-based procurement.
-
FDA temperature-management recalls: design lessons for AIRCHILL risk management
FDA Class II recalls affecting Blanketrol II and CoolBlue highlight failure-mode, alarm and fail-safe requirements for future temperature-management systems.
-
Heatstroke 2026: post-stabilisation hypothermia at 35 °C shows no benefit
A 2026 pilot randomized trial found no outcome benefit from maintaining heatstroke patients at 35 °C after initial cooling, while arrhythmias, gastrointestinal injury and shivering treatment increased.
-
ICECAP 2026: cooling duration after cardiac arrest does not improve neurological outcome
ICECAP separates cooling duration from cooling timing: longer hypothermia at 33 °C did not improve neurological outcome, strengthening the need to study timing, route and thermal dose as distinct variables.